{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:19:40Z","timestamp":1794359980026,"version":"4.9.0"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is increased risk of cardiovascular disease in patients with chronic inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies have shown association between cardiovascular disease (eg, myocardial infarction, heart failure, stroke) and inflammatory bowel disease. Medications such as infliximab and adalimumab (monoclonal antibodies to tumor necrosis factor \u03b1) may help decrease the inflammatory burden and cardiovascular risk; however, there have been reports of hypertriglyceridemia and worsening of moderate to severe heart failure with these medications. Janus kinase inhibitors, such as tofacitinib, have been associated with hyperlipidemia and thromboembolism. We aim to discuss clinical and imaging modalities to assess cardiovascular risk in inflammatory bowel disease patients and review the role of various medications with respect to cardiovascular disease in this population.<\/jats:p>","DOI":"10.1093\/ibd\/izaa258","type":"journal-article","created":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T05:54:43Z","timestamp":1601099683000},"page":"1107-1115","source":"Crossref","is-referenced-by-count":33,"title":["Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"27","author":[{"given":"Preetika","family":"Sinh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Cross","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Maryland School of Medicine , Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,26]]},"reference":[{"key":"2022092419282637800_CIT0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jgh.12751","article-title":"Inflammatory bowel disease pathogenesis: where are we?","volume":"30","author":"Fiocchi","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"2022092419282637800_CIT0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0004","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.cgh.2018.04.031","article-title":"Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases","volume":"16","author":"Aniwan","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0005","doi-asserted-by":"crossref","first-page":"e56944","DOI":"10.1371\/journal.pone.0056944","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death\u2013a Danish nationwide cohort study","volume":"8","author":"Kristensen","year":"2013","journal-title":"PLoS One."},{"key":"2022092419282637800_CIT0006","first-page":"izy354","article-title":"Risk of myocardial infarction in inflammatory bowel disease: a population-based national study","author":"Panhwar","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0007","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cgh.2007.09.016","article-title":"The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study","volume":"6","author":"Bernstein","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0009","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/gut.2010.228585","article-title":"Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study","volume":"60","author":"Kappelman","year":"2011","journal-title":"Gut."},{"key":"2022092419282637800_CIT0010","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut."},{"key":"2022092419282637800_CIT0011","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/ibd\/izx089","article-title":"Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases","volume":"24","author":"Nguyen","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.14740\/jocmr2102w","article-title":"Inflammatory bowel disease as a risk factor for premature coronary artery disease","volume":"7","author":"Ruisi","year":"2015","journal-title":"J Clin Med Res."},{"key":"2022092419282637800_CIT0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut."},{"key":"2022092419282637800_CIT0014","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/01.MIB.0000441200.10454.4f","article-title":"Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population","volume":"20","author":"Tsai","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2011.63","article-title":"Inflammatory bowel disease is associated with an increased incidence of cardiovascular events","volume":"106","author":"Yarur","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2022092419282637800_CIT0016","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0017","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.autrev.2017.01.009","article-title":"Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis","volume":"16","author":"Tektonidou","year":"2017","journal-title":"Autoimmun Rev."},{"key":"2022092419282637800_CIT0018","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1160\/TH14-11-0921","article-title":"Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies","volume":"113","author":"Ambrosino","year":"2015","journal-title":"Thromb Haemost."},{"key":"2022092419282637800_CIT0019","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/ijms20092154","article-title":"Inflammatory, serological and vascular determinants of cardiovascular disease in systemic lupus erythematosus patients","volume":"20","author":"Mercurio","year":"2019","journal-title":"Int J Mol Sci."},{"key":"2022092419282637800_CIT0020","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0021","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0022","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0023","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum."},{"key":"2022092419282637800_CIT0024","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/BOR.0000000000000528","article-title":"Cardiovascular disease in systemic lupus erythematosus: an update","volume":"30","author":"Liu","year":"2018","journal-title":"Curr Opin Rheumatol."},{"key":"2022092419282637800_CIT0025","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1177\/0961203314551083","article-title":"Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study","volume":"23","author":"Lerang","year":"2014","journal-title":"Lupus."},{"key":"2022092419282637800_CIT0026","first-page":"709","article-title":"The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study","volume":"56","author":"Hermansen","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"2022092419282637800_CIT0027","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/2047487314546826","article-title":"Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis","volume":"22","author":"Ballocca","year":"2015","journal-title":"Eur J Prev Cardiol."},{"key":"2022092419282637800_CIT0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2459\/JCM.0000000000000149","article-title":"Inflammatory bowel disease, liver diseases and endothelial function: is there a linkage?","volume":"16","author":"Ciccone","year":"2015","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"2022092419282637800_CIT0029","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(03)00699-1","article-title":"Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation","volume":"125","author":"Hatoum","year":"2003","journal-title":"Gastroenterology."},{"key":"2022092419282637800_CIT0030","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.crohns.2013.02.001","article-title":"Endothelial function and cardiovascular risk in active inflammatory bowel diseases","volume":"7","author":"Principi","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2022092419282637800_CIT0031","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cgh.2008.10.021","article-title":"Evidence of endothelial dysfunction in patients with inflammatory bowel disease","volume":"7","author":"Roifman","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0032","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/MPG.0000000000002252","article-title":"Measurement of microvascular function in pediatric inflammatory bowel disease","volume":"68","author":"Winderman","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2022092419282637800_CIT0033","first-page":"115","article-title":"Subclinical cardiac involvement in Crohn\u2019s disease and ulcerative colitis: an echocardiographic case-control study","volume":"58","author":"Vizzardi","year":"2016","journal-title":"Panminerva Med."},{"key":"2022092419282637800_CIT0034","doi-asserted-by":"crossref","first-page":"e010942","DOI":"10.1161\/JAHA.118.010942","article-title":"Inflammation and aortic pulse wave velocity: a multicenter longitudinal study in patients with inflammatory bowel disease","volume":"8","author":"Zanoli","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"2022092419282637800_CIT0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/CIRCULATIONAHA.112.093245","article-title":"The assessment of endothelial function: from research into clinical practice","volume":"126","author":"Flammer","year":"2012","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0036","doi-asserted-by":"crossref","first-page":"11304","DOI":"10.3748\/wjg.v21.i40.11304","article-title":"Arterial structure and function in inflammatory bowel disease","volume":"21","author":"Zanoli","year":"2015","journal-title":"World J Gastroenterol."},{"key":"2022092419282637800_CIT0037","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ecco-jcc\/jjy164","article-title":"Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals","volume":"13","author":"Aarestrup","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2022092419282637800_CIT0038","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/CIRCOUTCOMES.114.000918","article-title":"Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study","volume":"7","author":"Kristensen","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"2022092419282637800_CIT0039","doi-asserted-by":"crossref","first-page":"e0201991","DOI":"10.1371\/journal.pone.0201991","article-title":"Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease","volume":"13","author":"Le Gall","year":"2018","journal-title":"PLoS One."},{"key":"2022092419282637800_CIT0040","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/ajg.2009.81","article-title":"Risk of arterial thrombotic events in inflammatory bowel disease","volume":"104","author":"Ha","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"2022092419282637800_CIT0041","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MEG.0000000000001072","article-title":"Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications","volume":"30","author":"Herzog","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0042","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","article-title":"Inflammation and atherosclerosis: the end of a controversy","volume":"136","author":"Hansson","year":"2017","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0043","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/ibd\/izy157","article-title":"Heart under attack: cardiac manifestations of inflammatory bowel disease","volume":"24","author":"Mitchell","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0044","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ijcard.2016.08.101","article-title":"Cardiovascular disease in patients with inflammatory bowel disease: an issue in no guidelines land","volume":"222","author":"Zuin","year":"2016","journal-title":"Int J Cardiol."},{"key":"2022092419282637800_CIT0045","doi-asserted-by":"crossref","first-page":"3012509","DOI":"10.1155\/2019\/3012509","article-title":"Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies","volume":"2019","author":"Bunu","year":"2019","journal-title":"Gastroenterol Res Pract."},{"key":"2022092419282637800_CIT0046","article-title":"Inflammatory bowel disease and acute coronary syndromes: from pathogenesis to the fine line between bleeding and ischemic risk","author":"Pepe","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0047","doi-asserted-by":"crossref","first-page":"2568569","DOI":"10.1155\/2018\/2568569","article-title":"Vascular endothelial dysfunction in inflammatory bowel diseases: pharmacological and nonpharmacological targets","volume":"2018","author":"Gravina","year":"2018","journal-title":"Oxid Med Cell Longev."},{"key":"2022092419282637800_CIT0048","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.humimm.2011.04.005","article-title":"Association between NOD2\/CARD15 polymorphisms and coronary artery disease: a case-control study","volume":"72","author":"Galluzzo","year":"2011","journal-title":"Hum Immunol."},{"key":"2022092419282637800_CIT0049","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jacc.2014.02.606","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk","volume":"63","author":"Andrus","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"2022092419282637800_CIT0050","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol."},{"key":"2022092419282637800_CIT0051","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/art.38944","article-title":"The ability of the 2013 American College of Cardiology\/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores","volume":"67","author":"Kawai","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"2022092419282637800_CIT0052","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/art.40532","article-title":"Impact of changes in inflammation on estimated ten-year cardiovascular risk in rheumatoid arthritis","volume":"70","author":"Yu","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"2022092419282637800_CIT0053","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J."},{"key":"2022092419282637800_CIT0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","article-title":"Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications","volume":"77","author":"Palombo","year":"2016","journal-title":"Vascul Pharmacol."},{"key":"2022092419282637800_CIT0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-144-4-200602210-00006","article-title":"Preclinical carotid atherosclerosis in patients with rheumatoid arthritis","volume":"144","author":"Roman","year":"2006","journal-title":"Ann Intern Med."},{"key":"2022092419282637800_CIT0056","first-page":"61","article-title":"Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis","volume":"35","author":"Kao","year":"2008","journal-title":"J Rheumatol."},{"key":"2022092419282637800_CIT0057","first-page":"2047487320916589","article-title":"Imaging subclinical atherosclerosis in cardiovascular risk stratification","author":"Kozakova","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"2022092419282637800_CIT0058","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/08916934.2013.856005","article-title":"Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus","volume":"47","author":"Gustafsson","year":"2014","journal-title":"Autoimmunity."},{"key":"2022092419282637800_CIT0059","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0003319716652031","article-title":"Subclinical atherosclerosis in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"68","author":"Wu","year":"2017","journal-title":"Angiology."},{"key":"2022092419282637800_CIT0060","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007003","article-title":"Inflammation and aortic stiffness: an individual participant data meta-analysis in patients with inflammatory bowel disease","volume":"6","author":"Zanoli","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"2022092419282637800_CIT0061","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/00365521.2015.1070901","article-title":"Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase","volume":"51","author":"Principi","year":"2016","journal-title":"Scand J Gastroenterol."},{"key":"2022092419282637800_CIT0062","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J."},{"key":"2022092419282637800_CIT0063","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J."},{"key":"2022092419282637800_CIT0064","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"2022092419282637800_CIT0065","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med."},{"key":"2022092419282637800_CIT0066","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"2022092419282637800_CIT0067","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2015-208995","article-title":"Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis","volume":"75","author":"Ljung","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0068","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2022092419282637800_CIT0069","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther."},{"key":"2022092419282637800_CIT0071","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"2022092419282637800_CIT0072","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0073","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med."},{"key":"2022092419282637800_CIT0074","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/art.22418","article-title":"Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study","volume":"56","author":"Davis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2022092419282637800_CIT0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/ard.51.2.152","article-title":"Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus","volume":"51","author":"MacGregor","year":"1992","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0076","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3473","article-title":"Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"2022092419282637800_CIT0077","doi-asserted-by":"crossref","first-page":"e0139745","DOI":"10.1371\/journal.pone.0139745","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: cohort study using the general practice research database","volume":"10","author":"Close","year":"2015","journal-title":"PLoS One."},{"key":"2022092419282637800_CIT0078","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092419282637800_CIT0079","first-page":"466","article-title":"5-Aminosalicylic acid-associated myocarditis and pericarditis: a narrative review","volume":"69","author":"Brown","year":"2016","journal-title":"Can J Hosp Pharm."},{"key":"2022092419282637800_CIT0080","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1572-0241.1998.468_2.x","article-title":"Severe symptomatic sinus bradycardia associated with mesalamine use","volume":"93","author":"Asirvatham","year":"1998","journal-title":"Am J Gastroenterol."},{"key":"2022092419282637800_CIT0081","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J Exp Med."},{"key":"2022092419282637800_CIT0082","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd1929","article-title":"COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs","volume":"5","author":"Mitchell","year":"2006","journal-title":"Nat Rev Drug Discov."},{"key":"2022092419282637800_CIT0083","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","article-title":"Coxibs and cardiovascular disease","volume":"351","author":"Fitzgerald","year":"2004","journal-title":"N Engl J Med."},{"key":"2022092419282637800_CIT0084","first-page":"319","article-title":"Understanding the mechanism of 5-ASA in treating colonic inflammation","volume":"4","author":"Desreumaux","year":"2008","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2022092419282637800_CIT0085","doi-asserted-by":"crossref","first-page":"389720","DOI":"10.1155\/2009\/389720","article-title":"Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats","volume":"2009","author":"Zhang","year":"2009","journal-title":"Mediators Inflamm."},{"key":"2022092419282637800_CIT0086","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2022092419282637800_CIT0087","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med."},{"key":"2022092419282637800_CIT0088","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hc3501.096063","article-title":"Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model","volume":"104","author":"Kadokami","year":"2001","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0089","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0090","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2012-202136","article-title":"Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist","volume":"72","author":"Solomon","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0091","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0016-5085(17)30607-8","article-title":"Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"152","author":"Fumery","year":"2017","journal-title":"Gastroenterology."},{"key":"2022092419282637800_CIT0092","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut."},{"key":"2022092419282637800_CIT0093","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0094","year":"2019"},{"key":"2022092419282637800_CIT0095","author":"ClinicalTrials.gov"},{"key":"2022092419282637800_CIT0096","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology."},{"key":"2022092419282637800_CIT0097","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0098","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"2022092419282637800_CIT0099","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0100","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1161\/CIRCULATIONAHA.104.533463","article-title":"Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis","volume":"112","author":"Hauer","year":"2005","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0101","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"2022092419282637800_CIT0102","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol."},{"key":"2022092419282637800_CIT0103","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"2022092419282637800_CIT0104","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","article-title":"Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092419282637800_CIT0106","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY Consortium","volume":"113","author":"Narula","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092419282637800_CIT0107","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092419282637800_CIT0108","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2022092419282637800_CIT0109","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","article-title":"Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases","volume":"17","author":"Meserve","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0110","doi-asserted-by":"crossref","first-page":"e0225572","DOI":"10.1371\/journal.pone.0225572","article-title":"Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system","volume":"14","author":"Cross","year":"2019","journal-title":"PLoS One."},{"key":"2022092419282637800_CIT0111","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-156-5-201203060-00007","article-title":"Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study","volume":"156","author":"Ananthakrishnan","year":"2012","journal-title":"Ann Intern Med."},{"key":"2022092419282637800_CIT0112","article-title":"Daily aspirin use does not impact clinical outcomes in patients with inflammatory bowel disease","author":"Patel","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0113","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/01.CIR.0000124715.27937.78","article-title":"Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects","volume":"109","author":"Capone","year":"2004","journal-title":"Circulation."},{"key":"2022092419282637800_CIT0114","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCRESAHA.110.223883","article-title":"Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins","volume":"107","author":"Spite","year":"2010","journal-title":"Circ Res."},{"key":"2022092419282637800_CIT0115","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"Bmj."},{"key":"2022092419282637800_CIT0116","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2011.04194.x","article-title":"Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation","volume":"9","author":"Ulrych","year":"2011","journal-title":"J Thromb Haemost."},{"key":"2022092419282637800_CIT0117","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol."},{"key":"2022092419282637800_CIT0118","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s10620-013-2614-0","article-title":"Dyslipidemia and inflammation in patients with inflammatory bowel disease","volume":"58","author":"Karaahmet","year":"2013","journal-title":"Dig Dis Sci."},{"key":"2022092419282637800_CIT0119","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10620-012-2508-6","article-title":"The fatty acid profile of the erythrocyte membrane in initial-onset inflammatory bowel disease patients","volume":"58","author":"Uchiyama","year":"2013","journal-title":"Dig Dis Sci."},{"key":"2022092419282637800_CIT0120","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ibd\/izz098","article-title":"Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state","volume":"25","author":"Diab","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0121","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1194\/jlr.M700176-JLR200","article-title":"Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn\u2019s disease","volume":"48","author":"van Leuven","year":"2007","journal-title":"J Lipid Res."},{"key":"2022092419282637800_CIT0122","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282637800_CIT0123","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"key":"2022092419282637800_CIT0124","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","article-title":"Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?","volume":"69","author":"Garg","year":"2020","journal-title":"Gut."},{"key":"2022092419282637800_CIT0125","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s10620-019-5474-4","article-title":"Impact of angiotensin II signaling blockade on clinical outcomes in patients with inflammatory bowel disease","volume":"64","author":"Jacobs","year":"2019","journal-title":"Dig Dis Sci."},{"key":"2022092419282637800_CIT0126","doi-asserted-by":"crossref","first-page":"e97193","DOI":"10.1371\/journal.pone.0097193","article-title":"Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease","volume":"9","author":"Arab","year":"2014","journal-title":"PLoS One."},{"key":"2022092419282637800_CIT0127","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MEG.0000000000001016","article-title":"\u03b2-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study","volume":"30","author":"Willemze","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2022092419282637800_CIT0128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/CEG.S243478","article-title":"Cardiovascular risk in individuals with inflammatory bowel disease","volume":"13","author":"Biondi","year":"2020","journal-title":"Clin Exp Gastroenterol."},{"key":"2022092419282637800_CIT0129","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2018.12.032","article-title":"Aortic stiffness in patients with inflammatory bowel disease reduced after anti-tumor necrosis factor therapy","volume":"73","author":"Zanoli","year":"2019","journal-title":"J Am Coll Cardiol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/7\/1107\/45992739\/izaa258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/7\/1107\/45992739\/izaa258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T15:30:36Z","timestamp":1664033436000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/7\/1107\/5911946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,26]]},"references-count":129,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,9,26]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa258","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,9,26]]}}}